Prudential PLC Has $7,731,000 Stake in Athersys, Inc. (ATHX)
Prudential PLC held its stake in Athersys, Inc. (NASDAQ:ATHX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,120,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Prudential PLC owned 4.49% of Athersys worth $7,731,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Wells Fargo & Company MN lifted its holdings in Athersys by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 2,800 shares in the last quarter. Bank of America Corp DE lifted its holdings in Athersys by 17.2% in the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 9,019 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Athersys by 329.7% in the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 56,345 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Athersys in the 2nd quarter worth $113,000. Finally, Blair William & Co. IL lifted its holdings in Athersys by 708.0% in the 2nd quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 70,804 shares in the last quarter. 19.08% of the stock is owned by hedge funds and other institutional investors.
In related news, insider William Lehmann, Jr. sold 15,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $2.38, for a total value of $35,700.00. Following the transaction, the insider now directly owns 527,380 shares in the company, valued at approximately $1,255,164.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 9.40% of the company’s stock.
Athersys, Inc. (ATHX) opened at 2.42 on Friday. Athersys, Inc. has a one year low of $1.02 and a one year high of $2.63. The firm has a 50-day moving average of $2.06 and a 200-day moving average of $1.65. The firm’s market cap is $275.66 million.
Athersys (NASDAQ:ATHX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The business had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.96 million. During the same period last year, the business posted ($0.08) EPS. Athersys’s revenue was up 12.4% compared to the same quarter last year. Analysts anticipate that Athersys, Inc. will post ($0.24) EPS for the current year.
A number of equities analysts have commented on ATHX shares. Zacks Investment Research lowered shares of Athersys from a “buy” rating to a “hold” rating in a report on Thursday, August 31st. Maxim Group set a $12.00 price objective on shares of Athersys and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $7.17.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Want to see what other hedge funds are holding ATHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athersys, Inc. (NASDAQ:ATHX).
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.